# A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

> **NCT04293185** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Genetix Biotherapeutics Inc.** · enrollment: 35 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **GENETIC:** bb1111

## Key facts

- **NCT ID:** NCT04293185
- **Lead sponsor:** Genetix Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-14
- **Primary completion:** 2027-05
- **Final completion:** 2027-11
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04293185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04293185, "A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04293185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*